|
Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 10578
© 2008 American Society of Clinical Oncology
Liposarcoma treatment: Role of radiotherapy and chemotherapy
A. Longhi,
S. Neri,
C. Speranza,
M. Alberghini,
C. Ferrari,
M. Abate,
M. Cesari,
S. Ferrari,
E. Palmerini and
M. Mercuri
Instituto Ortopedico Rizzoli, Bologna, Italy; Policlinico S’Orsola-Malpighi, Bologna, Italy
10578
Background: The best adjuvant treatment for soft tissue sarcomas is still unclear. Soft tissue sarcomas is an eterogenous group of several different hystotypes. The aim of this retrospective study is to evaluate prognostic factors and treatments. Methods: All liposarcoma cases evaluated in our Pathology from Jan 1985 to December 2005 were reviewed: 299 cases of liposarcoma were found of these only 155 were treated at Rizzoli since their first diagnosis. Metastatic since diagnosis and pediatric cases were excluded. Of these 155 pts only 122 had localized liposarcoma of soft tissue and adequate informations and follow up. Results: Male were 71 and female 51, Median age 47 (15–85). Histology was as follows: mixoid 62, round cell 33, pleomorphic 27. Grading according to FNCCL was G1=18, G2=51, G3=53. Median tumor volume was 183 cm3 (8–3,800), mean 401. Surgical margins were adequate in 84 patients (66.4%) unadequate in 34 (27.9%), 4 missing. Treatment received were: 18 no treatment besides surgery, presurgery radiotherapy (PRE-RT) alone in 52 pts, postsurgery RT (POST- RT) alone in 30 pts, chemotherapy ± RT in 22 patients. Chemotherapy was based on anthracyclin and ifosfamide scheme (3–5 cycles), RT was ranging from 4,000–4,500 cGy. Five years DFS was 50 months for all group (range 1–230) and 5 yrs OS was 64 ms (10–230). Positive prognostic factors were grading, adequate margins and mixoid histology. Then excluding 18 pts who were G1 we evaluate on the remaining 104 patients, all G 2 an 3, the 5 yrs DFS and OS according to the treatment received. 5 yr DFS was 64% for those who received no-Tx, 56.5% for those who received PRE-RT and 82% for those who received POST RT, and 55.4 for those who received chemotherapy. 5-yr OS was 80% for no-Tx group, 81% for PRE-RT, 92% for POST-RT and 79% for chemo group. OS according to histology (on 104 pts, excluding G1) was 90% for mixoid, 82.8% for round cells and 74% for pleomorphic. At multivariate analysis grading and therapy (RT POST) maintain positive significance. Conclusions: From this retrospective study POST -RT seems to be the best treatment for localized liposarcoma.
No significant financial relationships to disclose.
Abstract presentation from the 2008 ASCO Annual Meeting
|
